U.K. agency suggests restriction on use of drug-eluting stents

09/24/2008 | FDAnews

The use of drug-eluting stents should be limited to coronary-artery disease patients who would likely require future interventions if they received a conventional bare-metal stent instead, according to a final guidance from the U.K.'s National Institute for Health and Clinical Excellence. NICE's final guidance offers data on specific drug-coated stents and their individual prices.

View Full Article in:

FDAnews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC